Inhibition of the replicative cycle of hepatitis C virus
Richard Bethell, George Kukolj and Peter W. White
It is estimated that 170 million people globally are infected with the hepatitis C virus (HCV). Chronic HCV infection can result in the development of liver cirrhosis and hepatocellular carcinoma, and therefore represents a substantial public health problem. Current drugs against HCV have poor safety profiles and limited effectiveness, especially against HCV genotype 1. As a result, there is considerable interest in identifying specific inhibitors of HCV replication that could be used either as an adjunct to current therapy or in place of it. A free poster from Nature Reviews Microbiology summarizes the replicative cycle of HCV and the principal targets for specific antiviral agents that are currently being developed.